C. Bettonica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
C. Bettonica has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- F. Estremiana
Esofagogastric Unit, Bellvitge University Hospital, de La Feixa Llarga, s/n L´Hospitalet de Llobregat, Barcelona, Spain
1 shared publication - Humberto Aranda
Bellvitge University Hospital, Spain
1 shared publication - Leandre Farran
Unitat de Cirurgia Esofagogàstrica i Bariàtrica, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Unitat de Reconstrucció Esofàgica Complexe (UREC), Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
1 shared publication - Mónica Miró
Department of Surgery, Hospital Universitari de Bellvitge, 08907 L’Hospitalet de Llobregat, Spain
1 shared publication - Sandra López Gordo
General and Digestive Surgery Department, Hospital Universitario de Mataró, 08304 Mataró, Spain
1 shared publication
Latest Publications
- 19 April 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 53 (2) , 451-459
Gastric and Small Intestine Gist: Results of 156 Cases in 20 Years
Purpose Gastric and small intestine are the most common gastrointestinal stromal tumors (GISTs). There are few studies of patients who underwent surgical treatment with disparate findings. We aimed to evaluate the differences between groups and the risk factors for recurrence and mortality. Methods A retrospective study of 96 gastric and 60 small intestine GIST was performed between 1995 and 2015. Both groups were compared in terms of clinicopathologic features, morbidity, recurrence, and mortality. Statistical analysis was performed with SPSS®. Results Eighty-one gastric GISTs and 56 small intestine GISTs underwent surgical treatment. Gastrointestinal bleeding was the most common cause of emergency surgery being more frequent in gastric GIST (P = 0.009); however, emergency surgery was indicated more frequently in the small intestinal GIST (P = 0.004) and was mostly due to perforation (P = 0.009). With a median follow-up of 66.9 (39.7–94.8) months, 28 (20.4%) patients had recurrence. A mitotic index > 5 (P ≤ 0.001) and the intestinal location (P = 0.012) were significantly associated to recurrence. Tumor size > 15 cm (P = 0.001) and an age of ≥ 75 years (P = 0.014) were associated to mortality. On univariate analysis, higher mean values of Ki-67 were associated to higher mortality (P = 0.0032). Small intestine GIST presented lower disease-free survival (DFS) than that of gastric GIST (65.7% vs 90.8%) with P = 0.003. The overall survival (OS) of gastric and small intestine GIST was 74.7% and 71.6%, respectively (P = 0.68). Conclusion Small intestine GIST received emergency surgery more frequently showing lower DFS and same OS than that of gastric GIST. We found that Ki-67 could be a prognostic factor. Further studies are necessary to assess whether Ki-67 is a prognostic risk factor for GISTs.
- 19 April 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 53 (2) , 451-459
Gastric and Small Intestine Gist: Results of 156 Cases in 20 Years
Purpose Gastric and small intestine are the most common gastrointestinal stromal tumors (GISTs). There are few studies of patients who underwent surgical treatment with disparate findings. We aimed to evaluate the differences between groups and the risk factors for recurrence and mortality. Methods A retrospective study of 96 gastric and 60 small intestine GIST was performed between 1995 and 2015. Both groups were compared in terms of clinicopathologic features, morbidity, recurrence, and mortality. Statistical analysis was performed with SPSS®. Results Eighty-one gastric GISTs and 56 small intestine GISTs underwent surgical treatment. Gastrointestinal bleeding was the most common cause of emergency surgery being more frequent in gastric GIST (P = 0.009); however, emergency surgery was indicated more frequently in the small intestinal GIST (P = 0.004) and was mostly due to perforation (P = 0.009). With a median follow-up of 66.9 (39.7–94.8) months, 28 (20.4%) patients had recurrence. A mitotic index > 5 (P ≤ 0.001) and the intestinal location (P = 0.012) were significantly associated to recurrence. Tumor size > 15 cm (P = 0.001) and an age of ≥ 75 years (P = 0.014) were associated to mortality. On univariate analysis, higher mean values of Ki-67 were associated to higher mortality (P = 0.0032). Small intestine GIST presented lower disease-free survival (DFS) than that of gastric GIST (65.7% vs 90.8%) with P = 0.003. The overall survival (OS) of gastric and small intestine GIST was 74.7% and 71.6%, respectively (P = 0.68). Conclusion Small intestine GIST received emergency surgery more frequently showing lower DFS and same OS than that of gastric GIST. We found that Ki-67 could be a prognostic factor. Further studies are necessary to assess whether Ki-67 is a prognostic risk factor for GISTs.